ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1513 • ACR Convergence 2022

    Identification of MRI Lesions Indicative of Spondyloarthritis Diagnosis from the Axial Spondyloarthritis International Society (ASAS) MRImagine Multi-Reader Scoring Dataset Using the Chi-Squared Automatic Interaction Detection Algorithm (CHAID)

    Stephanie Wichuk1, Walter P Maksymowych2, Robert G Lambert1, Abhilash Hareendranathan3 and Jacob Jaremko1, 1University of Alberta, Edmonton, AB, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Several types of active and structural lesions have been identified on sacroiliac joint MRI of spondyloarthritis (SpA) patients. Various combinations of these lesions may…
  • Abstract Number: 1542 • ACR Convergence 2022

    Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry

    Shery Susan Philip1, Ramya Janardana1, Revanesh S Mirji1, Chengappa Kavadichanda2, Devender Bairwa3, Geetabali Sircar4, Parasar Ghosh5, Anupam Wakhlu6, Padmanabha Shenoy7, Sumithra Selvam8 and Vineeta Shobha1, 1St. John’s Medical College Hospital, Bangalore, India, 2JIPMER, Pondicherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 4Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, 5Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 6Apollo Medics Super Speciality Hospitals, Lucknow, India, 7Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, 8Division of Epidemiology and Biostatistics, St. John’s Research Institute, St. John's Medical College Hospital, Bangalore, India

    Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…
  • Abstract Number: 1534 • ACR Convergence 2022

    Blood Flow Assessment of Digital Arterioles and Capillaries in Systemic Sclerosis Patients Using Ultra-high Resolution Doppler Ultrasounds

    Pietro Francesco Bica1, Riccardo Picasso2, Federico Pistoia2, Federico Zaottini2, Sara Sanguinetti2, Francesca Bovis3, Marta Ponzano3, Carmen Pizzorni1, sabrina Paolino1, Alberto Sulli1, Emanuele Gotelli1, Carlo Martinoli2 and Maurizio Cutolo1, 1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, 2Department of Health Sciences (DISSAL), University of Genova, Genova, Italy - IRCCS San Martino Polyclinic Hospital, Genova, Italy, 3Department of Health Sciences (DISSAL), University of Genova, Genova, Italy

    Background/Purpose: Systemic sclerosis (SSc) is a chronic connective tissue disease, characterized by the early occurrence of vasculopathy [1], easily detected by nailfold videocapillaroscopy (NVC) [2].…
  • Abstract Number: 1539 • ACR Convergence 2022

    Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease

    Monica Yang1, Seoyeon Lee2, Jessica Neely3, Marina Sirota2 and Paul Wolters2, 1UCSF, SF, CA, 2UCSF, SF, 3UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by diffuse fibrosis and vasculopathy that has potential to affect nearly every organ system. Interstitial lung…
  • Abstract Number: 1524 • ACR Convergence 2022

    Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort

    Ahmad Ramahi1, Alain Lescoat2, David Roofeh1, Vivek Nagaraja1, Rajaie Namas3, Suiyuan Huang1, John Varga1, David O’Dwyer1, Bonnie Wang1, Kevin Flaherty1, Ella Kazerooni1 and Dinesh Khanna4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, 4Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
  • Abstract Number: 1544 • ACR Convergence 2022

    Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica

    Justine D'agostino1, Valerie Devauchelle1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, Christophe Richez4, Marie Truchetet5, Daniel Wendling6, ERIC TOUSSIROT7, aleth Perdriger8, jacques-eric gottenberg9, Renaud FELTEN10, Bruno Fautrel11, laurent chiche12, Pascal HILLIQUIN13, Catherine Le Henaff14, Benjamin Dervieux15, Guillaume Direz16, Isabelle Chary-Valckenaere17, Divi CORNEC18, Dewi Guellec19, Thierry MARHADOUR20, Aghiles Souki19, Emmanule Nowak19 and Alain Saraux21, 1Université de Bretagne Occidentale, Brest, France, 2CHRU de Tours, Tours, France, 3LE MANS general hospital, LE MANS, France, 4Université de Bordeaux, Bordeaux, France, 5Bordeaux University Hospital, Bordeaux, France, 6CHU, University Teaching Hospital, Besançon, France, 7CHU de Besançon, Besançon, France, 8Rennes University, Rennes, France, 9Strasbourg University Hospital, Strasbourg, France, 10Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 11Pitié Salpêtrière Hospital, Paris, France, 12hopital europeen, Marseille, France, 13Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, 14Morlaix Hospital, Morlaix, France, 15Mulhouse Hospital, Mulhouse, France, 16Le Mans Hospital, Le Mans, France, 17Nancy University Hospital, Vandoeuvre, France, 18CHRU Brest, Brest, France, 19Brest University Hospital, Brest, France, 20CHU Cavale Blanche, Brest, France, 21CHU Brest, Brest, France

    Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…
  • Abstract Number: 1549 • ACR Convergence 2022

    Toward Safer Glucocorticoid Therapy

    Xingyu Pan1, Qiongqiong Hou1, Jiahui Xu1, Yake Ma1, Jiawen Li1, Min Li1, Jing Su1, Xuerou Shi1, William Bracken2 and David Katz2, 1WuXi AppTec, Nantong, China, 2Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
  • Abstract Number: 1541 • ACR Convergence 2022

    MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis

    Michael Hughes1, Stefano Di Donato2, Klodian Gjeloshi3, Giuseppina Abignano4, Fiammetta Danzo3, Giovanni Lettieri G4, Enrico De Lorenzis2, Dominic Bertham5, Philip O’Connor2, Olga Kubassova6 and Francesco Del Galdo2, 1Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, 3University of Campania ‘‘Luigi Vanvitelli’’, Napoli, Italy, 4Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Image Analysis Group, London, United Kingdom

    Background/Purpose: Fibroproliferative vasculopathy in systemic sclerosis (SSc) is caused by neointima proliferation is a key pathologic feature of SSc which results in arterial vessel narrowing…
  • Abstract Number: 1559 • ACR Convergence 2022

    Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines

    Yusuke Ushio1, Risa Wakiya2, Kiyo Ueeda3, Tomohiro Kameda2, shusaku nakashima4, Hiromi Shimada2, Mikiya Kato2, taichi miyagi5, Rina Mino6, Kanako Chujo7 and Hiroaki Dobashi8, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 2Kagawa University, Kagawa, Japan, 3Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 5Kagawa University, Kidagun, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

    Background/Purpose: Apremilast, the small-molecule phosphodiesterase -4 inhibitor, was approved for the treatment of recurrent oral ulcers associated with Behcet's disease (BD) in Japan from September…
  • Abstract Number: 1548 • ACR Convergence 2022

    Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients

    Guillermo CARVAJAL ALEGRIA1, Sara Boukhlal2, Sophie Hillion3, Pierre Pochard3, Emmanuelle Porchet3, Alain Saraux4, sandrine jousse joulin5, Thierry MARHADOUR6, Dewi Guellec3, Divi CORNEC7 and Valerie Devauchelle2, 1CHRU de Tours, Tours, France, 2Université de Bretagne Occidentale, Brest, France, 3CHRU de Brest, Brest, France, 4CHU Brest, Brest, France, 5Roche, Brest, France, 6CHU Cavale Blanche, Brest, France, 7CHRU Brest, Brest, France

    Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease. But it's pathophysiology and the impact of the treatments on immune cells are poorly known. Our objectives…
  • Abstract Number: 1556 • ACR Convergence 2022

    Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

    Alba Herrero-Morant1, José Luis Martín-Varillas2, Santos Castañeda3, Olga Maiz4, Julio Sánchez-Martín5, Norberto Ortego6, Enrique Raya7, Águeda Prior-Español8, Clara Moriano9, Rafael Melero10, Genaro Graña-Gil11, Ana Urruticoechea12, Angel Ramos13, Marta Loredo-Martínez14, Eva Salgado-Pérez15, Francisca Sivera16, Ignacio Torre17, F. Javier Narváez18, Jose Luis Andreu19, Olga Martinez20, Ricardo Gómez-de la Torre21, Sabela Fernandez-Aguado22, Susana Romero Yuste23, iñigo Gonzalez-Mazon5, Carmen Alvarez Reguera5, David Martínez-López5, José Luis Hernández5, Miguel Ángel González-Gay24 and Ricardo Blanco25, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital de Laredo, Laredo, Cantabria, Spain, 3Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 4Hospital Universitario de Donostia, San Sebastián, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Medicine Department, Universidad de Granada, Granada, Spain, 7Hospital San Cecilio, Granada, Spain, 8Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 9Complejo Asistencial Universitario de León, León, Spain, 10Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 11Hospital Universitario de A Coruña, A Coruña, Spain, 12Hospital Can Misses, Ibiza, Spain, 13Complejo Hospitalario de Soria, Soria, Spain, 14Hospital Clínico Lozano Blesa, Zaragoza, Spain, 15Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, 16Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 17Hospital de Basurto, Basurto, Spain, 18Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 20Hospital Clínico Universitario de Salamanca, Zamora, Spain, 21Hospital Universitario Central de Asturias, Oviedo, Spain, 22Hospital Universitario de Cabueñes, Gijon, Spain, 23Complexo Hospitalario Universitario, Pontevedra, Spain, 24Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 25Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
  • Abstract Number: 1536 • ACR Convergence 2022

    Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR

    Anna-Maria Hoffmann-Vold1, Cathrine Brunborg1, Paolo Airò2, Lidia P. Ananyeva3, László Czirják4, Serena Guiducci5, Eric Hachulla6, MENGTAO LI7, Carina Mihai8, Gabriela Riemekasten9, Petros P. Sfikakis10, Gabriele Valentini11, Otylia Kowal-Bielecka12, Yannick Allanore13 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 3V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 4Medical school of Pécs, Pecs, Hungary, 5University of Firenze, Firenze, Italy, 6University of Lille, Lille, France, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 9University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 10Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 11Università della Campania “Luigi Vanvitelli”, Napoli, Italy, 12Medical University of Bialystok, Bialystok, Poland, 13Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
  • Abstract Number: 1575 • ACR Convergence 2022

    Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Larson4, Cristina Burroughs5 and Peter Merkel6, 1Vanderbilt University Medical Center, Nashville, TN, 2University of California Los Angeles, Los Angeles, CA, 3Vasculitis Foundation, Chapel Hill, NC, 4Vasculitis Foundation, Kansas City, MO, 5University of South Florida, Tampa, FL, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
  • Abstract Number: 1572 • ACR Convergence 2022

    CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis

    Fernanda Genre1, Sara Remuzgo-Martinez1, Veronica Pulito-Cueto1, JOAO CARLOS BATISTA LIZ2, Diana Prieto-Peña1, Belén Atienza-Mateo1, Belén Sevilla-Pérez3, Javier Llorca4, Norberto Ortego5, María Teresa Leonardo6, Ana Peñalba6, F. Javier Narváez7, Luis Martín-Penagos8, Emilio Rodrigo8, Cristina Gomez-Fernandez9, Lara Belmar-Vega8, José A. Miranda-Filloy10, Luis Caminal-Montero11, Paz Collado12, Pedro Rodriguez-Jimenez13, Diego De Argila14, Patricia Quiroga-Colina15, Esther Vicente-Rabaneda16, Enrique Rubio17, Manuel León Luque17, Juan María Blanco-Madrigal18, Eva Galíndez-Agirregoikoa19, Javier Martín20, Santos Castañeda16, Ricardo Blanco21, Miguel Ángel González-Gay22 and Raquel Lopez Mejias23, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Ilerna, Madrid, Spain, 3Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, 5Medicine Department, Universidad de Granada, Granada, Spain, 6Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 7Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 8Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, 11Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 12Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, 13Dermatology Department, Hospital Universitario de La Princesa, Madrid, 14Dermatology Department, Hospital Universitario de La Princesa, Madrid, Spain, 15Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 16Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 17Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 18Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, 19Basurto University Hospital, Bilbao, Spain, 20Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, 21Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 22Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 23IDIVAL, Santander, Spain

    Background/Purpose: CD40 is a membrane glycoprotein expressed on B cells surface that activates antigen presenting cells [1]. BLK and BANK1 are components of B cells…
  • Abstract Number: 1580 • ACR Convergence 2022

    Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout

    Tate Johnson1, Lindsay Helget2, Harlan Sayles2, Punyasha Roul3, James O'Dell2, Ted Mikuls4 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3UNMC, Omaha, NE, 4Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
  • « Previous Page
  • 1
  • …
  • 438
  • 439
  • 440
  • 441
  • 442
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology